A refined understanding of immunosuppressives and cancer risk

Kidney International

Volumn 63, Issue 3, 2003, Pages 1160-1161

  Sukhatme, Vikas P ^b   Strom, Terry B ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Cyclosporine; Organ transplantation; Transforming growth factor ; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN; CYCLOSPORIN A; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHATIDYLINOSITOL 3 KINASE; POLYCLONAL ANTIBODY; RAPAMYCIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

APOPTOSIS; CANCER INCIDENCE; CANCER RISK; CELL MIGRATION; CELL SURVIVAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; ENDOTHELIUM CELL; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MOLECULAR BIOLOGY; NONHUMAN; ORGAN TRANSPLANTATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 12244267962     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00842.x     Document Type: Editorial

References (16)

1. PENN I: Post-transplant malignancy: The role of immunosuppression. Drug Saf 23:101-113, 2000
2. LUAN FL, DING R, SHARMA VK, et al: Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 63:917-926, 2003
3. HOJO M, MORIMOTO T, MALUCCIO M, et al: Cyclosporine induces cancer progression by a cell autonomous mechanism. Nature 397:530-534, 1999
4. LUAN FL, HOJO M, MALUCCIO M, et al: Rapamycin blocks tumor progression: Unlinking immunosuppression from antitumor efficacy. Transplantation 73:1565-1572, 2002
5. GUBA M, VON BREITENBUCH P, STEINBAUER M, et al: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 8:128-135, 2002
6. SCHREIBER SL, CRABTREE GR: The mechanism of action of cyclosporin A and FK506. Immunol Today 13:136-142, 1992
7. SCHMELZE T, HALL MN: TOR, a central controller of cell growth. Cell 103:253-262, 2000
8. DOUROS J, SUFFNESS M: New antitumor substances of natural origin. Cancer Treat Rev 8:63-87, 1981
9. ENG CP, SEHGAL SN, VEZINA C: Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo) 37:1231-1237, 1984
10. KARUMANCHI SA, MERCHAN J, SUKHATME VP: Renal cancer: Molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens 1:37-42, 2002
11. MAYERHOFER M, VALENT P, SPERR WR, et al: BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100:3767-3775, 2002
12. HUDSON CC, LIU M, CHIANG GG, et al: Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22:7004-7014, 2002
13. HUMAR R, KIEFER FN, BERNS H, et al: Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 16:771-780, 2002
14. TREINS C, GIORGETTI-PERALDI S, MURDACA J, et al: Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 277:27975-27981, 2002
15. FUJIKAWA K, DE AOS SCHERPENSEEL I, JAIN SK, et al: Role of PI 3-kinase in angiopoietin-1-mediated migration and attachment-dependent survival of endothelial cells. Exp Cell Res 253:663-672, 1999
16. JIANG BH, ZHENG JZ, AOKI M, VOGT PK: Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 97:1749-1753, 2000